Dashboard
Manage Tickers

EYPT EyePoint Pharmaceuticals, Inc.

Nasdaq eyepointpharma.com


$ 11.37 $ -0.05 (-0.44 %)    

Monday, 10-Nov-2025 12:10:03 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 619.01 $ 0.18 (0.03 %)
DIA $ 470.95 $ -0.90 (-0.19 %)
SPY $ 677.12 $ -0.06 (-0.01 %)
TLT $ 89.43 $ -0.07 (-0.08 %)
GLD $ 376.98 $ 1.07 (0.28 %)
$ 11.21
$ 11.48
$ 11.35 x 38
$ 11.37 x 106
$ 11.25 - $ 11.70
$ 3.91 - $ 14.91
1,204,048
na
928.04M
$ 1.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-08-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-04-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-10-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 03-12-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 11-09-2018 09-30-2018 10-Q
29 09-18-2018 06-30-2018 10-K
30 05-10-2018 03-31-2018 10-Q
31 02-08-2018 12-31-2017 10-Q
32 11-08-2017 09-30-2017 10-Q
33 09-13-2017 06-30-2017 10-K
34 05-08-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-Q
36 11-08-2016 09-30-2016 10-Q
37 09-13-2016 06-30-2016 10-K
38 05-06-2016 03-31-2016 10-Q
39 02-09-2016 12-31-2015 10-Q
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

eyepoint-pharmaceuticals-may-offer--sell-up-to-200m-common-stock-offering-with-cantor-fitzgerald
Eyepoint Pharmaceuticals May Offer & Sell ...
11/06/2025 23:25:09

- SEC Filing

rbc-capital-maintains-outperform-on-eyepoint-pharmaceuticals-raises-price-target-to-39
RBC Capital Maintains Outperform on EyePoi...
11/06/2025 15:54:17

RBC Capital analyst Lisa Walter maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and raises the price targ...

eyepoint-pharmaceuticals-q3-eps-085-misses-079-estimate-sales-966000k-miss-3329m-estimate
EyePoint Pharmaceuticals Q3 EPS $(0.85) Mi...
11/05/2025 12:01:08

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estima...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/15/2025 17:07:00

eyepoint-pharmaceuticals-raises-capital-as-it-advances-lead-product-to-pivotal-study
EyePoint Pharmaceuticals Raises Capital As...
10/15/2025 15:01:34

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

reported-earlier-eyepoint-prices-11m-shares-at-12-each-plus-15m-pre-funded-warrants-to-support-clinical-pipeline-expansion
Reported Earlier, EyePoint Prices 11M Shar...
10/15/2025 06:43:27

eyepoint-pharmaceuticals-announces-150m-proposed-public-offering-of-common-stock
EyePoint Pharmaceuticals Announces $150M P...
10/14/2025 20:37:23

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to develo...

eyepoint-pharmaceuticals-initiates-pivotal-phase-3-program-for-duravyu-to-treat-diabetic-macular-edema-expects-first-patient-dosage-in-q1-2026
EyePoint Pharmaceuticals Initiates Pivotal...
10/14/2025 20:03:26

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to develo...

chardan-capital-maintains-buy-on-eyepoint-pharmaceuticals-maintains-27-price-target
Chardan Capital Maintains Buy on EyePoint ...
08/07/2025 12:52:19

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $27 price ...

hc-wainwright--co-maintains-buy-on-eyepoint-pharmaceuticals-raises-price-target-to-23
HC Wainwright & Co. Maintains Buy on EyePo...
08/06/2025 16:38:07

HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and raises the price tar...

eyepoint-pharmaceuticals-q2-eps-085-misses-081-estimate-sales-5333m-miss-6627m-estimate
EyePoint Pharmaceuticals Q2 EPS $(0.85) Mi...
08/06/2025 11:03:20

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estima...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

eyepoint-completes-enrollment-for-second-phase-3-amd-trial-eyes-2026-data-for-duravyu
EyePoint Completes Enrollment For Second P...
07/29/2025 11:05:33

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to ...

forecasting-the-future-4-analyst-projections-for-eyepoint-pharmaceuticals
Forecasting The Future: 4 Analyst Projecti...
06/17/2025 18:00:42

rbc-capital-initiates-coverage-on-eyepoint-pharmaceuticals-with-outperform-rating-announces-price-target-of-28
RBC Capital Initiates Coverage On EyePoint...
06/17/2025 14:55:23

RBC Capital analyst Lisa Walter initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform rating and an...

analyst-expectations-for-eyepoint-pharmaceuticalss-future
Analyst Expectations For EyePoint Pharmace...
05/29/2025 19:00:31

hc-wainwright--co-reiterates-buy-on-eyepoint-pharmaceuticals-maintains-22-price-target
HC Wainwright & Co. Reiterates Buy on EyeP...
05/29/2025 16:13:29

HC Wainwright & Co. analyst Yi Chen reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $22 price...

heico-monro-abercrombie--fitch-joby-aviation-and-other-big-stocks-moving-higher-on-wednesday
Heico, Monro, Abercrombie & Fitch, Joby Av...
05/28/2025 14:23:37

eyepoint-pharma-enrolls-and-randomizes-over-400-patients-in-phase-3-lugano-pivotal-trial-of-duravyu-for-wet-amd-treatment
EyePoint Pharma Enrolls And Randomizes Ove...
05/27/2025 11:02:40

– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest ––  LUCI...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION